《復牌公告》創美藥業(02289.HK)控股股東擬出售內資股 今早復牌
創美藥業(02289.HK)公布,收到控股股東姚創龍的通知,其正與潛在買家討論收購姚創龍及其他內資股股東持有的總計4,011.25萬股內資股,合計佔公司已發行股本37.14%,姚創龍並已與潛在買家簽訂意向書。現時姚創龍持有5,900萬股內資股,佔公司已發行股本54.63%。
公司表示,根據該意向書,出售股份將分兩批轉讓予潛在買家。第一次交付時,姚創龍應將其持有的1,475萬股內資股轉讓予潛在買家,並促使其他內資股股東向潛在買家轉讓1,430萬股內資股。第一次交付後,潛在買家應持有2,905萬股內資股,佔公司已發行股本26.9%,姚創龍所持內資股則降至4,425萬股,佔公司已發行股本40.97%。第二次交付時,姚創龍應按與第一次交付相同的價格,將其持有的1,106.25萬股內資股轉讓予潛在買家,交付後,潛在買家應持有4,011.25萬股內資股,佔公司已發行股本總額的37.14%姚創龍持股則降至30.73%。
公告並指,買賣雙方尚未商定代價的最終數額,每股股份的最終轉讓價均須經國有資產監管部門批准,代價應以人民幣結算。公司申請於今早復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.